Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

•Development of IND/GLY was driven by a need to improve standards in COPD care•The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated•The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines•Availability of IND/GLY has helped optimise clinical practices in COPD management•Further research may confirm how dual bronchodilation can maximise patient care.